
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies is a company with strong partnerships and continued expansion, both in terms of its distribution infrastructure and its product offerings. While there are some risks involved, such as regulatory and financial risks, the company's innovative technology and increasing scientific validation make it a strong contender in the 3D bioprinting and medical aesthetics market. There is potential for further growth and success, but investors should consider the company's reliance on external financing and the possibility of dilution in the future.
Bears say
CollPlant Biotechnologies is facing challenges in the current capital environment and has recently experienced a disproportionately negative reaction in the stock due to a modest capital raise. While the company continues to advance its commercial programs and development pipeline, the success of its dermal filler partnership with AbbVie and potential contributions from its new logistics center will be key catalysts for market outlook and cashflow. The company's valuation, based on its rhCollagen technology platform in aesthetics and 3D bioprinting for breast implants, is highly dependent on assumptions and future capital raises, leading to a uncertain outlook.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares